Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Covidien PLC Raises FY 2013 Revenue Guidance


Friday, 25 Jan 2013 06:00am EST 

Covidien PLC updated its fiscal 2013 guidance to reflect the recent U.S. FDA approval of generic CONCERTA, the extension of the R&D tax credit and better operational performance thus far in the fiscal year. The Company now estimates that net sales in fiscal 2013 will be up 5% to 8%, including foreign exchange at current rates. This compares with prior guidance of a 3% to 6% sales increase in 2013. The Company reported revenue of $11.852 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $12.39 billion for fiscal 2013. 

Company Quote

91.37
0.37 +0.41%
11 Jul 2014